As doctors learn why GLP-1s don't work for about 50% of people, they are also learning more about the complex drivers of obesity. They foresee a future of personalized obesity medicine similar to the ...

A once-weekly injectable GIP/GLP-1 dual agonist conferred up to 22.5% weight loss at 48 weeks for adults with overweight or ...

Here & Now’s Peter O’Dowd spoke with Sarah Zhang, a reporter for The Atlantic, about how people are searching the web and using the app Telegram to buy next-generation GLP-3 drugs not yet approved by ...